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Terminalia catappa Linn bark is used to treat dysentery by various populations in
Southeast Asian countries, and its leaves have also been used in traditional medicine
to treat hepatitis in India and the Philippines. Here, the antifungal actions of crude
hydro-alcoholic extract (TcHE) and fractions from T. catappa leaves were assessed
via the agar diffusion and microdilution tests on Candida reference strains and clinical
isolates from patients with acquired immunodeficiency syndrome (AIDS). Additionally, the
potential cytotoxic effects of TcHE were assessed on cultured human peripheral blood
mononuclear cells (PBMC). T. catappa fractions and sub-fractions were analyzed by
gas chromatography coupled to mass spectrometry with electron impact (GC/MS/EI),
high-performance liquid chromatography coupled to mass spectrometry “electrospray”
ionization in positive mode (HPLC/MS/MS/ESI+) and hydrogen nuclear magnetic
resonance (1HNMR). TcHE and its fractions were able to inhibit the growth of all tested
Candida strains with the n-butanol (FBuOH) fraction presenting the best antifungal
activity. Testing of different FBuOH sub-fractions (SF) showed that SF10 was the most
active against Candida spp. Fractioning of SF10 demonstrated that 5 out of its 15
sub-fractions were active against Candida spp., with SF10.5 presenting the highest
activity. Chemical analysis of SF10 detected hydrolysable tannins (punicalin, punicalagin),
gallic acid and flavonoid C-glycosides. Overall, the results showed that T. catappa L. leaf
extract, fractions and sub-fractions were antifungal against Candida spp. and may be
useful to treat diseases caused by this fungus.
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INTRODUCTION
The increase number of individuals infected with human
immunodeficiency virus (HIV) has stimulated research
regarding Candida spp., which are opportunistic pathogens
responsible for one of the most common oral diseases affecting
immunosuppressed individuals, the oropharyngeal candidiasis
(OPC) (Hamza et al., 2008; Moura et al., 2010; Annapurna et al.,
2012). Though Candida albicans is the most frequently isolated
species as colonizer and pathogen of the oral mucosa, other
Candida species, such as Candida tropicalis, Candida krusei,
and Candida glabrata are recovered increasingly, mainly in
HIV-infected individuals (Gugnani et al., 2003; Hamza et al.,
2008; Patil et al., 2015). Candida yeasts cause oropharyngeal,
esophageal, laryngeal, and invasive candidiasis (Patil et al., 2015).
Ten to 49% of HIV patients die due to invasive fungal
infection (Favalessa et al., 2010). In addition, the constant use
of antifungal drugs in the past few decades has increased the
numbers of infection caused by resistant Candida strains. Thus,
special attention has been given to research focused on medicinal
plants to identify new molecules with antimicrobial potential
(Fyhrquist et al., 2002; Jagessar and Alleyne, 2011; Packer et al.,
2015).
Plants and their derived compounds have been used
worldwide for the prevention and treatment of diseases
(Triantafillidis et al., 2016). Terminalia catappa Linn. plant has
been investigated in various pharmaceutical studies as it contains
a variety of chemical components (Pandya et al., 2013; Yeh et al.,
2014). T. catappa L. leaf extracts exhibit biological activities,
including antioxidant (punicalagin, punicalin, terfluvina A and
B, chebulic acid, benzoic acid, cumaric, and its derivatives)
(Chen and Li, 2006; Chyau et al., 2006; Kinoshita et al.,
2007), antidiabetic (β-carotene) (Anand et al., 2015), anticancer
(punicalagin) (Naitik et al., 2012), antiviral (ellagic acid) (Tan
et al., 1991), anti-inflammatory (triterpenic acids, especially
ursolicacid and its derivatives) (Fan et al., 2004), antimicrobial
(flavones and flavanols) (Kloucek et al., 2005; Nair and Chanda,
Abbreviations: AIDS, Acquired Immunodeficiency Syndrome; ANOVA,
Analysis of Variance; ATB, Automation Triple Resonance Broadband; ATCC,
American Type Culture Collection; BSTFA+TMCS, N,O-bis (trimethylsilyl)
trifluoroacetamide with trimethylchlorosilane; CFU, Colony Forming Units;
CLSI, Clinical and Laboratory Standards Institute; DMSO, Dimethyl Sulfoxide;
FAcOEt, Ethyl acetate fraction; FBuOH, n-butanol fraction; FHEX, Hexane
fraction; GC/MS/EI, Gas Chromatography coupled to Mass Spectrometry
withElectron Impact ionization; HIV, Human Immunodeficiency Virus;
1HNMR, Nuclear Magnetic Resonance of Hydrogen; HPLC/UV, High-
performance liquid chromatography coupled with Ultraviolet spectroscopy;
HPLC-MS/MS/ES+, Liquid Chromatography coupled to Electrospray
Ionization Mass Spectrometry in positive mode; MIC, Minimum Inhibitory
Concentration; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide; NIST/EPA/NIH, National Institute of Standard and Technology
Mass Spectral Library/Environmental Protection Agency/National institutes of
Healthy; OPC, Oropharyngeal Candidiasis; PBMC, Human Peripheral Blood
Cell; RPMI, Roswell Park Memorial Institute medium; SD, Standard Deviation;
SDA, Sabouraud Dextrose Agar; SF, Sub-fractions; SF10-FbuOH, FBuOH sub-
fraction 10; TcHE, Terminalia catappa Hydroalcoholic Extract; TIC, Total
Ion Chromatogram; TMS, Tetramethylsilane; UFMA, Federal University of
Maranhão.
2008; Shinde et al., 2009), and hepato-protective activities
(punicalagin, punicalin) (Kinoshita et al., 2007).
In India, a plaster of T. catappa leaves is used to treat
scabies, leprosy wounds and other skin diseases (Nair and
Chanda, 2008). Its traditional use includes the treatment of
diarrhea and fever, especially in India, the Philippines and
Malaysia (Kloucek et al., 2005; Shinde et al., 2009). Previous
studies suggest that the most polar fractions obtained from
T. catappa leaves are effective against bacteria (Shinde et al., 2009)
and fungi (Jagessar and Alleyne, 2011), but little is known of
T. catappa effects against Candida spp. Here, we investigated
the antifungal properties of the hydroalcoholic extract obtained
from T. catappa leaves (TcHE). We also assessed the antifungal
actions of fractions and sub-fractions (SF) obtained from TcHE.
Additionally, compounds of the most effective SF were identified.
MATERIALS AND METHODS
Plant Materials and Extraction
T. catappa Linn (Combretaceae) leaves were collected in São José
de Ribamar, Maranhão, and identified by the Attic Herbarium
Seabra of the Federal University of Maranhão (São Luís, Brazil)
under the voucher specimen n◦. 01062. The leaves were dried
at room temperature for 1 week. The dried material was then
triturated in a slicer to obtain a fine powder. Two hundred grams
of powder were extracted twice with 600 ml of ethanol (70%,
v/v) at room temperature for 2 days with an 8 h-period between
extractions. The mixture was filtered through cellulose filter
paper (Whatman No. 1, GE Healthcare UK, Amersham, UK) and
concentrated on a rotary evaporator (Büchi Labortechnik AG,
Flawil, Switzerland) under reduced pressure at 40◦C.
The crude hydro-alcoholic extract (TcHE) was lyophilized,
then (200 g) resuspended in 600 ml MeOH/H2O (Merck,
Darmstadt, Germany) (80:20, v/v). The samples were
sequentially subjected to liquid-liquid partition with hexane
(Merck, Darmstadt, Germany), followed by ethyl acetate (Merck,
Darmstadt, Germany), then n-butanol (Merck, Darmstadt,
Germany), resulting in three fractions with different polarities:
the hexane fraction (FHEX), which was the least polar fraction;
the ethyl acetate fraction (FAcOEt) with intermediate polarity;
and the n-butanol fraction (FBuOH), the most polar fraction.
The resulting fractions were concentrated on a rotary evaporator
(Büchi Labortechnik AG, Flawil, Switzerland), lyophilized
(VirTis Lyophilizer Tray Dryer, New York, United States),
weighed and stored in sterile glass containers at−20◦C.
Isolation and Identification of Candida
Strains
Candida spp. samples were obtained from the buccal mucosa
of 52 patients with acquired immunodeficiency syndrome
(AIDS) attending the Hospital Presidente Vargas in São
Luis, Brazil, after a written informed consent was obtained.
Individuals (30 male and 22 female) were 19–61 years old.
Samples were collected by rubbing sterile swabs on the oral
mucosa, and were then inoculated into tubes containing
0.85% saline (ISOFAR, Paraná, Brazil). Candida spp. were
isolated in CHROMagar (Difco, Detroit, MI, USA) and
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incubated at 37◦C for 48 h. The biochemical identification
of the yeast was performed in automated Vitek-2 R© system
(Compact, bioMérieux, Marcy-L ‘Etoile, France), according to
the manufacturer’s recommendations. The study was reviewed
and approved by the Ethics Committee of the Federal University
of Maranhão (UFMA) under the protocol number 23115-006
540/2009-40.
Monitoring of Antifungal Activity
Microdilution Assay
The antifungal activities of TcHE, FHEX, FAcOEt, and FBuOH
were evaluated in 20 clinical isolates (14 Candida albicans, 2
Candida glabrata, 2 Candida tropicalis, and 2 Candida krusei)
and three reference strains (C. albicans ATCC 90028, C. glabrata
ATCC 2001, and C. krusei ATCC 6258) of Candida spp. based
on the proposal of the Clinical and Laboratory Standards
Institute (CLSI) M27-A3 (CLSI, 2008). References strains were
kindly donated by the São Paulo State University, Araraquara
Dental School, São Paulo, Brazil. The antifungal effects of all
FBuOH SFs (primary and secondary) were initially assessed
against two clinical isolates of C. albicans (C. albicans 02 and
C. albicans 04) and the reference strain C. albicans ATCC 90028
in the agar diffusion method using cavity plates (McGinnis,
1980). The effects of the most active SFs were also evaluated
in the microdilution method, against Candida spp. reference
strains and four clinical isolates (C. albicans 02, C. glabrata 01,
C. tropicalis 01, C. krusei 02), one from each species of Candida.
In order to determine antifungal activities in themicrodilution
assay, the TcHE and its fractions were diluted in RPMI-
1640 culture medium (Sigma-Aldrich, St. Louis, MO, USA) at
concentrations of 0.18–48 mg/ml and were incubated in 96-well
plates (at 37◦C, for 48 h) with Candida spp. (2.5× 103 CFU/ml),
as recommended by the CLSI M27-A3 protocol (CLSI, 2008).
Fluconazole (0.25–64µg/ml; Pfizer, Brazil) and amphotericin B
(0.0625–16µg/ml; Sigma-Aldrich, St. Louis, MO, USA) were
used as positive controls. Vehicle (RPMI)-treated wells were
used as negative controls. Following incubation, the absorbance
was read at 540 nm in a microplate reader (BioMérieux Reader
250 Version 2.0.5, Genève, Suisse). All tests were performed in
triplicate.
In a separate series of experiments, the most active SFs were
tested at concentrations of 0.2–56 or 0.18–48µg/ml, depending
on their initial amount. In all experiments, the absorbance
obtained from wells containing either TcHE, fractions or SFs
plus medium and inoculum was discounted from those obtained
from wells containing extract, fractions or SFs plus medium only.
Then, the percentages of Candida spp. growth inhibition were
determined for each strain using the formula outlined below:
% Inhibition = (Ac− At)/Ac× 100
Where Ac= control absorbance and At= test absorbance.
The MIC of each compound was defined as the lowest
concentration at which no fungal growth was observed.
Agar Diffusion Assay
The antifungal effects of FBuOH SFs were evaluated in the
agar diffusion method (Moody et al., 2004). Briefly, 20 ml of
Sabouraud dextrose agar medium (SDA) (Difco Laboratories,
Detroit, MI, USA) containing chloramphenicol were added to
Petri dishes (100 × 200 mm in diameter) according to the
manufacturer’s recommendations. After solidification, the plates
were incubated for 24 h at 37◦C to assess contamination. Then,
Candida spp. (100µl of standardized inoculum solution with
103 CFU/ml) was seeded on the plates with sterile swabs.
Fifty-microliter extract volumes at different concentrations were
added into perforations of approximately 5 mm in diameter in
solid culture medium. Fluconazole (64µg/ml) (Pfizer, SP, Brazil)
and saline (0.9%) were used as positive and negative controls,
respectively. All tests were performed in triplicate. The inhibition
zones were measured in millimeters, and the data were analyzed
by performing statistical tests.
Human Peripheral Blood Cell (PBMC)
Viability
PBMCs were collected from 20 healthy human volunteers
(non-smoking donors who had not received any medication
for the last 15 days prior to sampling, aged 18–35 years
old) who provided written formal consent. This study was
approved by the Ethics Committee in Research of Ceuma
University (protocol number: 105/2014). Cells were obtained
by the standard method of density-gradient centrifugation over
Histopaque R©-1119 according to the manufacturer’s instructions.
PBMCs were then suspended in a supplemented DMEM
culture medium (Life Technologies, Brazil) containing 10%
fetal bovine serum (Life Technologies, Brazil), streptomycin
(100µg/ml; Sigma–Aldrich, Brazil) and penicillin (100 U/ml;
Sigma–Aldrich, Brazil). PBMCs were plated in 96-well plates (2
× 105 cells/well in 200µl) and incubated with either phosphate-
buffered saline (PBS; negative control), or TcHE (0.001–10
mg/ml). Lipopolysaccharide (LPS)-treated wells were used as
positive control. Cells were incubated at 37◦C in a 5% CO2
atmosphere for 24 h. Then 100µl of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT, 2 mg/ml in PBS;
Sigma-Aldrich, Brazil) were added to each well and the plates
were incubated for 4 h at 37◦C. Following incubation, the
supernatants were removed and the formazan crystals formed
were dissolved in 100µl of 100% DMSO. Absorbances were
read at 540 nm using a spectrophotometer. All experiments
were performed three times in triplicate. Citotoxicity was then
classified as follows: (i) 0 - not cytotoxic (inhibition below 25%);
(ii) 1- slightly cytotoxic (inhibition between 25 and 50%); (iii)
2-moderately cytotoxic (inhibition between 50 and 75%) and
(iv) 3-intensely cytotoxic (inhibition higher than 75%). Besides
statistical analysis, the results were also evaluated in accordance
with ISO standard 10993-5.
Investigation of Plant Components
The crude hydro-alcoholic extract of T. catappa Linn, as well as
FHEX, FAcOEt, and FBuOH, were subjected to phytochemical
analysis based on the tests proposed by Matos (1998) to search
for phenols, tannins, flavones, xanthones, flavonols, flavanoids,
and triterpene steroids. This survey aimed to identify the
classes of natural products (called secondary or functional plant
metabolites) present in this extract.
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Fractionation of Extracts Using a
Sephadex® LH-20
After determining the antifungal activity of TcHE and its different
fractions, the FBuOH (44.13 mg) fraction was sub-fractionated
in a Sephadex R© LH-20 (Sigma-Aldrich, St. Louis, MO, USA)
column (5 × 100 cm) using methanol (Merck, Darmstadt,
Germany) as the mobile phase. For this, the eluate was pumped
at a flow rate of 500 ml/h for 4 h and then, 15 SFs were collected
(25 ml/tube). The SFs exhibiting the greatest antifungal activities
were identified, mixed and fractionated. The antifungal effects of
these resulting SFs were also assessed againstCandida spp. via the
agar diffusion and microdilution methods.
Chemical Analysis
Gas Chromatography Coupled to Mass Spectrometry
with Electron Impact Ionization (GC/MS/EI)
TcHE, FHEX, FAcOEt, and FBuOH samples were derivatized
with N,O-bis (trimethylsilyl) trifluoroacetamide with
trimethylchlorosilane (BSTFA+TMCS, 99:1, v/v) (Sigma-
Aldrich, St. Louis, MO, USA). The samples were analyzed using
an Agilent 6890 gas chromatograph (Agilent Technologies, Inc.,
Santa Clara, CA) and mass spectrometry (Agilent 5973N MSD)
with an HP-5 Agilent R© (0.25 mm × 30 m × 0.25µm) column
under the following conditions: 230◦C injection temperature,
250◦C interface, 200◦C ion source with a helium carrier gas flow
of 1 ml/min. The column oven temperature increased as follows:
5 min of heating (70◦C), gradient of 5◦C/min up to 310◦C.
High-Performance Liquid Chromatography Coupled
with Ultraviolet Spectroscopy (HPLC/UV)
A total ion chromatogram (TIC) was obtained using an Agilent
Varian ProStar HPLC system equipped with a ProStar 325
UV-Vis detector (ProStar 325, Varian, Palo Alto, USA) and a
C18 column (Pursuit, Agilent Technologies, Inc., Santa Clara,
CA, USA), which was protected with a guard column. For the
mobile phase, pump A utilized Milli-Q water (Millipore-Merck,
Darmstadt, Germany) acidified with 0.1% acetic acid; Pump
C used HPLC-grade acetonitrile (Merck, Darmstadt, Germany)
and pump B used methanol (HPLC grade, Merck, Darmstadt,
Germany) to clean the column. The program used for elution was
carried out from 0 to 15 min with gradient ranged from 95% A
and 0.5% C to 72% A and 28% C. Then the gradient ranged from
72% A and 28% C to 32% A to 68% C in the interval between
16 and 55 min, reaching the concentration of 100% for C in the
interval of 55–60 min. The detection of compounds of interest
was performed at a wavelength (λ) of 254 nm, and the volume
injected was 20µl, with the mobile phase flow set at 0.6 ml/min.
Liquid Chromatography Coupled to Electrospray
Ionization Mass Spectrometry in Positive Mode
(HPLC-MS/MS/ES+)
This analysis was performed to determine the molecular masses
of positive ions detected and to identify the components present
in FBuOH and its sub-fractions. The analyses were conducted
using a 10AD-VP chromatographic system coupled with a
Shimadzu SPD-M10AVP DAD detector (Shimadzu, Kyoto,
Japan) and an Esquire 3,000 Plus-Ion Trap mass spectrometer
(Bruker Daltonics, GmbH, Bremen, Germany) equipped with a
4,000 V capillary, a nebulizer set at 27 psi, a drying gas flux of 7
l/min, and a temperature of 320◦C, in positive ion mode.
Nuclear Magnetic Resonance of Hydrogen (1HNMR)
To identify the compounds present in FBuOH sub-fraction 10
(SF10-FbuOH), this sub-fraction was subjected to analysis via 1H
nuclear magnetic resonance using a 300-MHz Varian Mercury
Plus spectrometer (VarianMedical Systems, Inc., CA, USA) (7.05
T) in CD3OD. Chemical shifts (δ) were reported in ppm using
tetramethylsilane (TMS) as an internal reference standard, and
coupling constants (J) were given in Hz. The ATB (Automation
Triple Resonance Broadband) probe (5 mm inner diameter) was
used at room temperature and pulse 45 to detect 1H.
Statistical Analysis
Each experiment was performed in triplicate and results were
expressed as mean ± standard deviation (SD). To evaluate
the effects of the various fractions and sub-fractions on fungal
growth, we initially applied the Shapiro-Wilk test for normality.
Once the results were confirmed to be normally distributed, the
data were analyzed by ANOVA followed by Tukey’s test. Data
obtained from PBMC cell viability test were analyzed by ANOVA
followed by Dunnet’s test. The significance level was set at 5% for
all tests.
RESULTS
Distribution of Candida Species from
Mucosal Tissues
This study included 52 patients diagnosed with AIDS. Candida
cells were found in the oral cavities of 83% (43) patients,
with some of them (18.6%) colonized with multiple Candida
spp. As a result, 51 yeast strains were isolated. Of those,
56% were C. albicans (29/51), 12% were C. tropicalis (6/51),
12% were C. krusei (6/51), 8% were C. glabrata (4/51), 4%
were C. famata (2/51), 4% were C. parapsilosis (2/51), and 4%
were C. guilliermondii (2/51). The four most prevalent isolates of
Candida spp. were investigated in the antifungal activity assays.
Plant Material: Yield and Phytochemical
Analysis
Yields obtained for TcHE, FHEX, FAcOEt, and FBuOH were
depicted in Table 1 with FBuOH presenting the lowest one.
T. catappa TcHE, FHEX, FAcOEt, and FBuOH were subjected
to phytochemical screening according to the method described
TABLE 1 | The dry weights and yields of the hydro-alcoholic extract and
its fractions.
Weight of dry leaves TcHE FHEX FAcOEt FBuOH
1 kg (570 ml) 46.17 g 2.123 g 2.317 g 1.067 g
Yield 5.77% 0.26% 0.28% 0.13%
TcHE, crude hydro-alcoholic extract of T. catappa L.; FHEX, hexane fraction; FAcOEt, ethyl
acetate fraction; FBuOH, N-butanol fraction.
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by Matos (1998). The analysis revealed the presence of phenols,
tannins, flavones, flavonols, flavonoids, and triterpenes sterols
(Table 2).
Antifungal Activity
Antifungal assays were performed against different clinical and
reference strains of Candida. Both the TcHE and its fractions
TABLE 2 | Phytochemical analysis of the hydro-alcoholic extract and its
fractions.
Compounds class Terminalia catappa extracts
TcHE FHEX FAcOEt FBuOH
Phenols + + + +
Tannins + − + +
Flavones, xanthones, flavonols + + − +
Flavonoids + − − +
Triterpenes steroids + + − −
TcHE, crude hydro-alcoholic extract of T. catappa L.; FHEX, hexane fraction; FAcOEt, ethyl
acetate fraction; FBuOH, N-butanol fraction; (+), presence of substance; (−), absent of
substance.
were antifungal against all the tested strains of Candida when
assessed in the microdilution method (Table 3). However, their
antifungal potencies varied between strains. MIC values ranged
from 1.5 to 6 mg/ml for FHEX, 0.75 to 3 mg/ml for FBuOH,
0.75 to 6 mg/ml for FAcOEt and 0.75 to 12 mg/ml for TcHE
(Table 3). The MIC90 (minimum concentration able to inhibit
90% of strains) for TcHE, FHEX and FAcOEt was 3 mg/ml, but
1.5 mg/ml for FBuOH. FBuOH presented the lowest MIC values
(Table 3).
Amphotericin B, fluconazole, FHEX, FAcOEt, and TcHE
were compared to FBuOH in relation to the capacity of
Candida growth inhibition. Growth inhibition assays showed
that TcHE, FBuOH, and FAcOEt (1.5 mg/ml) presented the
best antifungal activities against all the tested reference strains
of Candida spp with percentage of inhibitions as high as
100% (Figures 1A–C). Significant differences were observed
across fractions with FHEX being the least active (p < 0.01
or p < 0.0001 depending on species, Figures 1A–C). Of
note, TcHE, FBuOH, and FAcOEt were more effective than
fluconazole (p < 0.0001) and amphotericin B (p < 0.05)
(Figures 1A–C). C. krusei ATCC 6258 was sensitive dose
dependent (SDD) to fluconazole (Figure 1C; MIC value of
16µg/ml).
TABLE 3 | Minimum inhibitory concentrations of amphotericin B, fluconazole, FHEX, FBuOH, FAcOEt, TcHE against Candida spp.
Strains Amphotericin B (µg/ml) Fluconazole (µg/ml) FHEX (mg/ml) FBuOH (mg/ml) FAcOEt (mg/ml) TcHE (mg/ml)
C. albicans 01 2 16 6 1.5 3 3
C. albicans 02 1 16 3 3 3 12
C. albicans 03 2 8 3 1.5 1.5 1.5
C. albicans 04 2 4 3 1.5 1.5 1.5
C. albicans 05 2 8 3 1.5 3 1.5
C. albicans 06 2 8 1.5 1.5 1.5 1.5
C. albicans 07 2 4 1.5 1.5 1.5 3
C. albicans 08 2 8 3 0.75 1.5 3
C. albicans 09 1 4 3 1.5 6 12
C. albicans 10 1 4 3 3 3 3
C. albicans 11 2 16 6 3 6 6
C. albicans 12 4 8 6 3 3 3
C. albicans 13 2 16 1.5 0.75 1.5 3
C. albicans 14 1 16 6 1.5 3 3
C. glabrata 01 2 16 1.5 1.5 1.5 3
C. glabrata 02 2 16 1.5 1.5 1.5 1.5
C. tropicalis 01 2 32 3 1.5 3 3
C. tropicalis 02 2 32 3 1.5 3 3
C. krusei 01 4 >64 1.5 1.5 1.5 2
C. krusei 02 4 32 1.5 1.5 1.5 3
C. albicans ATCC 90028 2 16 6 1.5 1.5 1.5
C. glabrata ATCC 2001 2 16 6 1.5 0.75 0.75
C. krusei ATCC 6258 0.5 16 3 0.75 0.75 0.75
MIC50* 2 16 3 1.5 1.5 1.5
MIC90** 2 16 3 1.5 3 3
MIC range 1–4 4–> 64 1.5–6 0.75–3 0.75–6 0.75–12
*MIC50, MIC value that inhibited 50% of the strains.
**MIC90, MIC value that inhibited 90% of the strains.
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When tested against C. albicans ATCC 90028, MIC values
were of 6 mg/ml for FHEX, and 1.5 mg/ml for FBuOH, FAcOEt,
and TcHE. Also, MIC values were of 6 mg/ml for FHEX, 1.5
mg/ml for FBuOH, and 0.75mg/ml for FAcOEt and TcHE against
C. glabrata ATCC 2001. FHEX (3 mg/ml), FBuOH, FAcOEt, and
TcHE (0.75 mg/ml) were all able to inhibit C. krusei ATCC 6258
growth (Table 3).
Figures 2A–D represented some of the best results of
antifungal potential of TcHE and its fractions against four
clinical isolates, one from each species, at 1.5 mg/ml. FBuOH
FIGURE 1 | Inhibitory effect of fluconazole and amphotericin B (clinically used antifungal agents), TcHE, FAcOEt, FBuOH, and FHEX on Candida
reference strains growth. (A) Candida albicans ATCC 90028; (B) Candida glabrata ATCC 2001; (C) Candida krusei ATCC 6258. The concentrations used were:
1.5, 8, and 2µg/ml for TcHE and its fractions, fluconazole and amphotericin B, respectively. Inhibitory action of each substance was compared to that of FBuOH. *p <
0.05, **p < 0.01, and ***p < 0.0001 were considered to be significant.
FIGURE 2 | Inhibitory effect of fluconazole and amphotericin B (clinically used antifungal agents), TcHE, FAcOEt, FBuOH, and FHEX on Candida
clinical samples growth. (A) Candida albicans; (B) Candida glabrata; (C) Candida tropicalis; (D) Candida krusei. The concentrations used were: 1.5, 8, and 2µg/ml
for TcHE and its fractions, fluconazole and amphotericin B, respectively. Inhibitory action of each substance was compared to that of FBuOH. *p < 0.05, **p < 0.01,
and ***p < 0.0001 were considered to be significant.
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showed better antifungal activity than TcHE (p < 0.0001)
and FAcOEt (p < 0.05) against C. albicans clinical strain
(Figure 2A). Amphotericin B (p < 0.0001) and fluconazole
(p < 0.05) presented higher activity in comparison to that
observed for FBuOH (Figure 2A). Similarly, FBuOH presented
the best activity on C. glabrata and C. tropicalis clinical isolates
(p < 0.0001, Figures 2B–C). These effects were even more
pronounced than those observed for either fluconazole or
amphotericin B (p < 0.0001, Figures 1B,C). When evaluated
against C. krusei clinical isolates, FBuOH and FHEX were the
most effective, followed by FAcOEt (p < 0.0001, Figure 2D).
C. krusei and C. tropicalis clinical samples were SDD to
fluconazole (Figures 2C–D), with MIC values of 16µg/ml
(Table 3).
As FBuOH was found to exhibit the best antifungal activity,
we next assessed the antifungal properties of its sub-fractions
(SF 1–15), by using the agar diffusion test. Figure 3 illustrates
the test results for a clinical isolate. Of those sub-fractions,
only SF 7–14 were antifungal (112µg/ml) (Figure 3). SF 10
(SF10-FBuOH) presented the largest inhibition zone (p < 0.001,
Figure 3). We next assessed the antifungal actions of SF10-
FBuOH (0.2–56µg/ml) in the microdilution test against four
clinical isolates and reference strains.
FIGURE 3 | Boxplots of the mean values and standard deviations of the
sizes of the inhibition zones caused by activity of specific FBuOH
sub-fractions (SF 7–14). ANOVA and Tukey’s test (p < 0.001) showed that
the SF10-FBuOH had a significant greater inhibition zone size than the other
sub-fractions tested (*p < 0.05).
SF10-FBuOH MIC values ranged from 7 to 56µg/ml, with
the lowest value being registered against the C. albicans isolate.
Both the MIC50 (minimum concentration able to inhibit 50% of
strains) and the MIC90 (minimum concentration able to inhibit
90% of strains) were 28µg/ml (Table 5).
SF10-FBuOH was then fractionated and the resultant sub-
fractions (SF 10.1–10.10) were evaluated in the agar diffusion
method against C. albicans ATCC 90028 and two C. albicans
clinical isolates. Only SF 10.5–10.10 were antifungal, with SF 10.5
being the most active sub-fraction (p < 0.05). Table 4 depicted
the results when SF 10.5–SF 10.10 were tested at 96µg/ml. This
antifungal action was further confirmed in the microdilution test.
SF 10.5 MIC values ranged from 6 to 48µg/ml with the lowest
value being registered against the C. tropicalis isolate. MIC50 was
of 24µg/ml and MIC90 was 48µg/ml (Table 5).
PBMC Viability
The cytotoxic effects of TcHE were evaluated on PBMC. Overall,
TcHE was not cytotoxic, only reducing cell viability at very high
concentrations (5–10 mg/ml) in comparison with vehicle-treated
controls (p< 0.05, Figure 4).
TABLE 5 | Minimum inhibitory concentration (µg/mL) of amphotericin B,
fluconazole, SF10-FBuOH and SF- 10.5 against Candida spp.
Strains Amphotericin B Fluconazole SF10-FBuOH SF-10.5
C. albicans 02 8 16 7 24
C. glabrata 01 8 16 28 24
C. tropicalis 01 8 32 28 6
C. krusei 02 8 >64 28 48
C. albicans ATCC
90028
8 32 28 24
C. glabrata ATCC
2001
8 64 14 24
C. krusei ATCC
6258
4 16 14 48
MIC50* 8 32 28 24
MIC90** 8 64 28 48
MIC range 4–8 16–> 64 7–28 6–48
*MIC50, MIC value that inhibited 50% of the strains.
**MIC90, MIC value that inhibited 90% of the strains.
TABLE 4 | Antifungal potential of sub-fractions SF 10.5, SF 10.6, SF 10.8, SF 10.9, and SF 10.10, derived from sub-fraction SF10-FBuOH, evaluated by the
antifungal agar diffusion test against Candida albicans ATCC 90028 and two clinical specimen of Candida albicans.
C. albicans strains SF10 sub-fractions
SF 10.5 SF 10.6 SF 10.8 SF 10.9 SF 10.10 FLZ
ATCC 90028 15 ± 0.81 12.33 ± 1.24 11.33 ± 1.24 9.67 ± 0.47 8.67 ± 1.24 6.33 ± 0.44
Ca 02 15 ± 1.0 14 ± 2.64 14.66 ± 1.52 10.66 ± 1.15 9.97 ± 0.46 5.33 ± 1.25
Ca 04 15.33 ± 1.25 11.67 ± 1.24 10.66 ± 1.69 9.33 ± 1.24 9.33 ± 0.47 10.43 ± 0.62
Inhibition zones size is expressed in mm; FLZ, fluconazole (64µg/ml).
The antifungal activity was obtained from three independent experiments done in triplicate at a concentration of 96µg/ml.
The ANOVA test was applied where each value represents the mean ± the standard deviation (SD) of the inhibition zones size (mm).
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Chemical Analysis and Identification of the
Components of FBuOH and SF10-FBuOH
Total ion chromatography (TIC) of SF10-FBuOH revealed
a chromatographic peak with a retention time of 30 min
corresponding to gallic acid. The probability of this compound
being gallic acid was 90% according to the NIST/EPA/NIH Mass
Spectral Library (National Institute of Standards and Technology,
Gaithersburg, MD).
Analysis of FBuOH using the HPLC-DAD/MS/MS/ESI+
system revealed 10 chromatographic peaks with two major
peaks: peak number 4, with a retention time (Rt) of 10.943
min (28.639%) and peak 7 with a Rt of 13.839 min (21.089%)
FIGURE 4 | PBMC cell viability after exposure to different
concentrations of TcHE. Symbol (*) represents statistical differences
between the control and experimental groups (ANOVA one way followed by
Dunnet test, p < 0.05).
(Figure 5). These peaks were accompanied by their respective
absorption spectra in the ultraviolet region (Figure 6). The
maximum wavelengths (maxλ) of the absorption bands for all
peaks were characteristic of the galagil chromophore, at 218,
260, and 379 nm and demonstrated varying intensities for
the absorption band at 218 nm (Figure 6). Thus, FBuOH of
T. catappa is rich in compounds found in the ellagitannins
(hydrolyzable tannins) class.
The MS1/MS2/ES+ system was used in FBuOH and SF10-
FBuOH, which allowed us to determine the molecular weights of
the positive ions detected and to identify the components in sub-
fractions rich in ellagitannins and other classes of compounds,
such as C-flavonoid glycosides (Figure 7). In the chromatogram
for FBuOH, the ion [M+H+] detected at the MS RT of 9.2
min showed a mass to charge (m/z) ratio of [M+H+] = 1.103,
which was compatible with the molecular formula C48H30O31
for which M = 1,102 Da, which was identified as an ellagitannin
acid derived from punicalagin. The ion [M+H+] detected at
the MS1 RT of 9.5 min had an m/z ratio of [M+H+] = 783,
detected for fragments with m/z = 765 (100%), m/z = 680 and
m/z= 621. This mass was compatible with themolecular formula
C34H22O22, for which M = 782 Da, and was identified as an
ellagitannin acid derivative of punicalin.
The structural formulas proposed for the compounds in
FBuOH were shown in Figure 8 based on LC/MS/ES+ analysis
of the ions detected with retention times in the range of 9.2–11.5
min in FBuOH.
The 1HNMR spectra demonstrated the chemical shift of
signals (δ, or ppm), with data for SF10-FBuOH revealing two
additional intense signals at δ = 3.3 and 4.8, which were derived
from the CH3OH and H2O non-deuterated solvents. The signal
FIGURE 5 | Analysis of LC/DAD and HPLC/DAD data for SF10-FBuOH. (A) The chromatographic profile and a table containing the RTs and areas (%) of peaks
detected at 254 nm. HPLC detected 10 peaks in FBuOH, with RTs ranging from 9.404 to 16.115 min. The major peaks were peaks 4 (RT = 10.943 min) and 7
(RT = 13.013 min). (B) The ultraviolet absorption spectra of the major peak was at 4:07.
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FIGURE 6 | An analysis of the LC/MS/MS/IES data for SF10-FBuOH. (A) MS2 with ions detected by TIC. (B) The MS2 peak with RT = 9.2 min (punicalagin).
(C) The EM2 peak with RT = 9.5 min (punicalin).
in the δ = 6.4–6.82 region corresponded to hydrogens of the
aromatic ring, and the signal in the δ = 3.98–4.2 region referred
to the methinic hydrogens of a sugar moiety, while δ = 2.15 in
the form of multiple signals was assigned to the sugar methylene
group (CH2) (Figure 8).
The expansion of the 1HNMR spectra of the δ 8.4–3.8
region revealed signals of chemical shift at δ = 8.5 attributed
to one acid hydroxyl (OH), confirming the presence of free
carboxyl groups for the structure with M = 1,102 Da. Signals
with different coupling constants were also identified in the
δ 5.5–4.9 region which could be attributed to the anomeric
hydrogens of the α β structures derived from punicalin and
punicalagin. Therefore, chromatographic studies of FBuOH and
its sub-fractions revealed a compound formed by hydrolyzable
tannins (punicalin and punicalagin), gallic acid and C-flavonoid
glycosides.
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FIGURE 7 | Structures proposed by the results of the MS/MS/ES+ analysis for ions detected at RTs ranging from 9.2 to 11.5 min in SF10-FBuOH.
(A) The pseudomolecular ion [M+H+] = 1,103 (RT = 9.2 min) and molecular mass of M = 1,102 for the molecular formula C48H28O31, which was identified as an
ellagitannin acid derivative of punicalagin. (B) The pseudomolecular ion [M+H+] = 783 (RT = 9.3 min) with a molecular mass of M = 782 for molecular formula
C34H22O22, identified as punicalin. (C) The pseudomolecular ion [M+H
+] = 338 M for the formula C14H10O10, which was identified as ellagic acid dihydrate.
(D,E) Ellagic acid derivative. (F) Isovitexin derivative (2′′-O –galloyl).
DISCUSSION
This study confirmed the high frequency of oral candidiasis
in hospitalized patients with AIDS (83%), as reported in other
studies, demonstrating the development of one or more fungal
infections in 80–95% of patients during the course of their illness
(Bouza and Muñoz, 2008; Junqueira et al., 2012). C. albicans
was the most prevalent species (56%), while the prevalence of
all “non-albicans” Candida spp. was 44%, which is in agreement
with other studies (Favalessa et al., 2010; de Paula et al., 2015).
In general, patients with HIV/AIDS manifest approximately
five episodes of oral candidiasis per year (Favalessa et al., 2010).
Frequent episodes of fungal infection in immunosuppressed
patients and the use of antifungal drugs have selected for fungal
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FIGURE 8 | The nuclear magnetic resonance spectrum of hydrogen (1H) detected using a 300-MHz Varian instrument in CD3 OD. The chemical shift
signals (δ or dpi) are shown for SF10-FBuOH.
strains resistant to antifungal drugs. In this study, fluconazole
inhibited less than 50% of all Candida strains tested, confirming
the development of fungal resistance in hospitalized patients with
AIDS.
The increased incidence of antimicrobial-resistant Candida
isolates has highlighted the need for novel and more potent
therapies against this microorganism. T. catappa L. is a plant
species that contains a wide variety of chemical components (Lin
et al., 2001; Kinoshita et al., 2007; Naitik et al., 2012) and is
widely used in the traditional medicine in India, Malaysia, and
Indonesia. However, studies addressing the antifungal properties
of T. catappa are scarce and little is known on the anti-Candida
activities of hydro-alcoholic extracts obtained from T. catappa
leaves. Recently, the crude ethanolic or aqueous extract from
the leaves of T. catappa L. was suggested to be more effective
against bacteria than Candida spp. (Jagessar and Alleyne, 2011).
This poor effect was attributed to the lower concentration of
substances active against filamentous fungi and C. albicans
(Jagessar and Alleyne, 2011; Mandloi et al., 2013) in these
preparations. Herein, we present novel and important evidence
on that the TcHE is antifungal against Candida spp., and that this
effect is due to the presence of antimicrobial compounds in the
FBuOH fraction. Also, TcHE had not cytotoxic actions on PBMC.
The results obtained demonstrate that FBuOH and FAcOEt
are more effective than TcHE and FHEX in reducing Candida
spp. growth (>90%). Of note, FBuOH actions were greater than
those observed for FAcOEt, as it presented the lowest MIC
values. Accordingly, fractionation of FBuOH showed its sub-
fractions SF7–14 present potent antifungal activities, specially,
SF10-FBuOH; suggesting the compounds recovered in this
sub-fraction exhibit superior antifungal activity. The antifungal
activity of SF10-FBuOH was further confirmed by isolation of
SF10.5, a sub-fraction of SF10-FBuOH which presented potent
antimicrobial actions against Candida spp.
The chemical analysis of SF10-FBuOH detected the presence
of hydrolysable tannins (punicalin and punicaligin), gallic acid
and C-flavonoid glycosides. It was previously demonstrated
that hydrolysable tannins, also called ellagitannins, are the
major chemical constituents of T. catappa leaves and that they
have been linked to the antitumor (Chen et al., 2000) and
antioxidant activities attributed to this plant (Kinoshita et al.,
2007). The same group of compounds has been associated
with a strong antimicrobial activity against bacteria and yeast
(Lim et al., 2006). This effect was suggested to involve
the precipitation of proteins or the removal of metal and
hydrogen ions from microbial enzymes, thereby modifying
vital metabolic processes in these microrganisms (Okuda,
2005; Costa et al., 2008). In addition to these hydrolysable
tannins, both gallic acid and the glycosylated phenols found
in FBuOH may contribute to its antifungal activity. This is
supported by findings in that the gallic acid obtained from
the air-dried mature Galla rhois methanolic extract and other
plants is antimicrobial (Ahn et al., 2005; Chanwitheesuk et al.,
2007). Glycosylated phenolic compounds isolated from natural
sources possess antifungal properties of interest. Particularly,
phenolic acids have shown promising in vitro and in vivo
activity against Candida species (Ozcelik et al., 2011; Teodoro
et al., 2015). Flavonoids, especially their glycosides, are
of great general interest due to their diverse bioactivity.
Flavonoid C-glycosides, obtained from different types of plans,
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have shown significant antioxidant activity, anticancer, and
antitumor activity, hepatoprotective activity, anti-inflammatory
activity, anti-diabetes activity, antiviral activity, antibacterial,
and antifungal activity, and other biological effects (Xiao et al.,
2016).
In conclusion, the FBuOH obtained from the TcHE of
T. catappa L. leaves is a potent antifungal against Candida spp.,
rich in hydrolysable tannins, gallic acid and glycosylated phenols.
Also, the low cytotoxic effects of TcHE support the use of FBuOH
or its derived sub-fractions and/or compounds as alternative
therapies for Candida-induced infections.
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